NanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman
- Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind
- Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of the technology platform
- Novel “nanosyringe” platform can deliver complex biologic payloads selectively and intracellularly, unlocking the interior of the cell for new intervention possibilities in unmet medical needs